Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

• Results Overview

  Crisaborole ointment was more effective than placebo at treating eczema symptoms and was found to be safe with mostly mild side effects when applied twice daily for 28 days.

• Study Summary

  Num Participants:

  None

  Study Type:

  Rct

  Control Group:

  Vehicle (Placebo) Ointment Applied Twice Daily

  Efficacy End Points Treatment:

  {'ISGA success': {'AD-301': 32.8, 'AD-302': 31.4}, 'ISGA clear/almost clear': {'AD-301': 51.7, 'AD-302': 48.5}}

  Efficacy End Points Control:

  {'ISGA success': {'AD-301': 25.4, 'AD-302': 18.0}, 'ISGA clear/almost clear': {'AD-301': 40.6, 'AD-302': 29.7}}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Various	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected